SITE009-0089

SITE009 (AUS) › SITE009-0089

SITE009-0089

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2025-12-21

enrolled

AEs

2

Serious

0

Dropout signal

–

Adverse events

2

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-27 (study day 216); relationship: NOT RELATED

moderate assessed

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-12-04 (study day 162); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.